Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3)-Reference-Cited by-同舟云学术

Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3)

Published:2019-10 Issue: Volume:85 Page:105835
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Heeney Matthew M.,Abboud Miguel R.,Amilon Carl,Andersson Marielle,Githanga Jessie,Inusa Baba,Kanter Julie,Leonsson-Zachrisson Maria,Michelson Alan D.,Berggren Anders R.

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Pharmacology (medical),General Medicine

Reference54 articles.

1. Pathophysiology and perioperative management of sickle cell disease;Paradowski;J. Perioper. Pract.,2015

2. Sickle cell disease;Bender,2003

3. Sickle-cell disease;Rees;Lancet,2010

4. Guideline on the management of acute chest syndrome in sickle cell disease;Howard;Br. J. Haematol.,2015

5. Association of coagulation activation with clinical complications in sickle cell disease;Ataga;PLoS One,2012

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sickle Cell Disease: Current Drug Treatments and Functional Foods with Therapeutic Potential;Current Issues in Molecular Biology;2024-06-12

2. Development of Purinergic Receptor Agonists and Antagonists;Purinergic Signaling in Neurodevelopment, Neuroinflammation and Neurodegeneration;2023

3. Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study;Blood;2022-09-29

4. Clinical Features and Outcome of Sickle Cell Disease in a Tertiary Center in Northern Lebanon: A Retrospective Cohort Study in a Local, Hospital-Associated Registry;Hemoglobin;2021-05-13

5. An evaluation of ticagrelor for the treatment of sickle cell anemia;Expert Review of Hematology;2020-09-24